Next 10 |
2024-05-19 01:10:48 ET Summary Anti-inflammatory drugs are likely to have limited effects on Alzheimer's disease because they are not stopping early oxidation and nitration. Neuroinflammation in Alzheimer's disease is primarily caused by oxidative and nitrosative stress. Inhib...
Ongoing progress toward last patient enrolled in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025...
2024-03-19 06:53:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclo Therapeutics (NASDAQ: CYTH ) just reported results for the fourth quarter of 2023. Cyclo Therapeutics reported earnings per share of -23 cents. The company repor...
2024-03-18 10:59:35 ET More on Cyclo Therapeutics Seeking Alpha’s Quant Rating on Cyclo Therapeutics Historical earnings data for Cyclo Therapeutics Financial information for Cyclo Therapeutics Read the full article on Seeking Alpha For further...
Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025 Aligned development strategy for Trappsol ...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the ...
Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority interest of 79% NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, I...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...
2023-12-28 10:00:05 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, and R1 RCM are Citi’s top stocks in healthcare For further details see:...
News, Short Squeeze, Breakout and More Instantly...
Cyclo Therapeutics Inc. Company Name:
CYTH Stock Symbol:
NASDAQ Market:
Ongoing progress toward last patient enrolled in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025...
Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025 Aligned development strategy for Trappsol ...